

Development of the drug discovery platform based on ^{64}Cu to expedite the R&D of new-generation drugs (LinqMed Inc.)



City	Year of Establishment	Founder
Chiba	2022	Yukie Yoshii Hiroaki Kurihara Hiroki Matsumoto Atsuo Waki

Partner VC	Latest round of Fundraising	Valuation
DBJ Capital Co., Ltd.	Series A	Non-Disclosure

Contact Information :

tel : +81-3-6661-7661

e-mai : linqmed@linqmed.co.jp

Website : <https://www.linqmed.net>

○ Business Plan

In this project, a large-scale production of ^{64}Cu will be developed. ^{64}Cu is a unique radioisotope that emits radiation for diagnostic and therapeutic purposes and that easily binds to a variety of molecules. This project will establish Japan's original drug discovery support platform that can rapidly develop "visible" cancer treatments using ^{64}Cu as new-generation drugs. This platform will create a new fundamental for the drug industry.

○ Research Outline

During this project period, we will collaborate with some companies to establish a drug discovery support platform based on ^{64}Cu . Through this, we will develop a large-scale RI production technology that will take on the challenge of creating the next generation pharmaceutical industry infrastructure, and aim to solve economic and social issues.

- (1) Establishment of a large-scale production technology of ^{64}Cu
- (2) Establishment of manufacturing technology for ^{64}Cu with high specific radioactivity
- (3) Long-term stabilization of ^{64}Cu pharmaceuticals

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
Healthcare	PCA 2023~2025FY	JPY 1,000 million	—